Eniola Olutogun’s research aligns well with NIH SBIR/STTR priorities, particularly in **neuropharmacology (CCT model), computational drug discovery (TOPOLOGIX, neurocascade), and AI-driven health applications (psyche-twin)**. Her independent researcher status and multi-domain expertise (pharmacist + computational modeler) make her a strong candidate for early-stage translational projects, though the U.S. business registration requirement may be a barrier. The NIH’s emphasis on **innovation, IP retention, and commercial potential** (e.g., neurocascade’s circuit simulation or TOPOLOGIX’s drug-resistance predictions) could fit her work, especially if framed as a **startup or academic-industry collaboration**.